Evidence map›Paper›PMID 28203441›Full record

ArticleJournal of thoracic disease2017

Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.

Kazuhiko Kotani, Maciej Banach

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Pleiotropic Effects of PCSK-9 Inhibitors.International journal of molecular sciences · 2021
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Inhibiting PCSK9 - biology beyond LDL control.Nature reviews. Endocrinology · 2018
    Review
  17. Review
  18. Management of Statin Intolerance in 2018: Still More Questions Than Answers.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2018
    Review
  19. Article
  20. Poststatin Lipid Therapeutics: A Review.Methodist DeBakey cardiovascular journal
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Kazuhiko KotaniDivision of Community and Family Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Maciej BanachDepartment of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipoprotein(a) [Lp(a)] has been identified as a risk factor for cardiovascular disease. Lp(a) levels are also high under certain clinical conditions, including familial hypercholesterolemia and high blood low-density lipoprotein (LDL) cholesterol levels. Few effective generic therapies for modulating Lp(a) have been developed. However, new therapies involving inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) using monoclonal antibodies have markedly reduced the blood LDL levels-and the Lp(a) levels as well. Much attention has therefore been focused on this therapy and its utility. The mechanism by which PCSK9 inhibitors reduce the Lp(a) levels remains unclear. We here describe the effects of PCSK9 inhibitors on Lp(a) and discuss potential mechanisms and perspectives of this topic.

Indexed as

Apolipoprotein(a) [apo(a)]apolipoprotein B (apoB)familiar hypercholesterolemiaLDL receptorLDL receptor-related protein (LRP)scavenger receptor (SR)

Identifiers

PMID28203441
PMCPMC5303088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.